The nonglycemic actions of dipeptidyl peptidase-4 inhibitors

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Kim, Na Hyung ^a   Yu, Taeyang ^b   Lee, Dae Ho ^b  

^a Wonkwang University   (South Korea)

^b Wonkwang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; ANTIDIABETIC AGENT; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; INSULIN;

ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CELL MEMBRANE; CELL PROLIFERATION; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; META ANALYSIS (TOPIC); NONHUMAN; OXIDATIVE STRESS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; VASCULAR SMOOTH MUSCLE CELL; VASOCONSTRICTION; BIOSYNTHESIS; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GENETICS; GLUCOSE BLOOD LEVEL; METABOLISM; PANCREAS ISLET BETA CELL; PATHOLOGY; SECRETION (PROCESS); VASCULAR SMOOTH MUSCLE;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MUSCLE, SMOOTH, VASCULAR; SIGNAL TRANSDUCTION;

EID: 84929057224     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/368703     Document Type: Review

References (100)

1. D. M. Nathan, "Finding new treatments for diabetes-how many, how fast⋯ How good?" The New England Journal of Medicine, vol. 356, no. 5, pp. 437-440, 2007.
2. S. Russell, "Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction, " International Journal of Clinical Pharmacy, vol. 35, no. 2, pp. 159-172, 2013.
3. D. J. Drucker and M. A. Nauck, "The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes, " The Lancet, vol. 368, no. 9548, pp. 1696-1705, 2006.
4. P. R. Flatt, C. J. Bailey, and B. D. Green, "Dipeptidyl peptidase IV (DPP IV) and relatedmolecules in type 2 diabetes, " Frontiers in Bioscience, vol. 13, no. 10, pp. 3648-3660, 2008.
5. J. R. Ussher and D. J. Drucker, "Cardiovascular biology of the incretin system, " Endocrine Reviews, vol. 33, no. 2, pp. 187-215, 2012.
6. S. Dalle, R. Burcelin, and P. Gourdy, "Specific actions of GLP-1 receptor agonists and DPP4 inhibitors for the treatment of pancreatic β-cell impairments in type 2 diabetes, " Cellular Signalling, vol. 25, no. 2, pp. 570-579, 2013.
7. J. S. Yoon and H. W. Lee, "Understanding the cardiovascular effects of incretin, " Diabetes andMetabolismJournal, vol. 35, no. 5, pp. 437-443, 2011.
8. R. Mentlein, "Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides, " Regulatory Peptides, vol. 85, no. 1, pp. 9-24, 1999.
9. M. D. Gorrell, V. Gysbers, and G. W. McCaughan, "CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes, " Scandinavian Journal of Immunology, vol. 54, no. 3, pp. 249-264, 2001.
10. M. Kirby, D. M. T. Yu, S. P. OConnor, and M. D. Gorrell, "Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition, " Clinical Science, vol. 118, no. 1, pp. 31-41, 2010.
11. C. L. Boland, M. DeGeeter, D. S. Nuzum, and M. Tzefos, "Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors, " Annals of Pharmacotherapy, vol. 47, no. 4, pp. 490-505, 2013.
12. O. J. Cordero, F. J. Salgado, and M. Nogueira, "On the origin of serum CD26 and its altered concentration in cancer patients, " Cancer Immunology, Immunotherapy, vol. 58, no. 11, pp. 1723-1747, 2009.
13. V. K. Hopsu-Havu and G. G. Glenner, "A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-β-naphthylamide, " Histochemie, vol. 7, no. 3, pp. 197-201, 1966.
14. P. Busek, R. Malik, and A. Sedo, "Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer, " International Journal of Biochemistry and Cell Biology, vol. 36, no. 3, pp. 408-421, 2004.
15. P. A. Havre, M. Abe, Y. Urasaki, K. Ohnuma, C. Morimoto, and N. H. Dang, "The role of CD26/dipeptidyl peptidase IV in cancer, " Frontiers in Bioscience, vol. 13, no. 5, pp. 1634-1645, 2008.
16. G. Ghersi, H. Dong, L. A. Goldstein et al., "Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex, "The Journal of Biological Chemistry, vol. 277, no. 32, pp. 29231-29241, 2002.
17. M. Chiravuri, F. Agarraberes, S. L. Mathieu, H. Lee, and B. T. Huber, "Vesicular localization and characterization of a novel post-proline-cleaving aminodipeptidase, quiescent cell proline dipeptidase, " The Journal of Immunology, vol. 165, no. 10, pp. 5695-5702, 2000.
18. V. Matheeussen, Y. Waumans, W. Martinet et al., "Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis, " Basic Research in Cardiology, vol. 108, no. 3, article 350, 2013.
19. H. Zhang, Y. Chen, F. M. Keane, and M. D. Gorrell, "Advances in understanding the expression and function of dipeptidyl peptidase 8 and 9, " Molecular Cancer Research, vol. 11, no. 12, pp. 1487-1496, 2013.
20. N. C. Foeger, A. J. Norris, L. M. Wren, and J. M. Nerbonne, "Augmentation of Kv4. 2-encoded currents by accessory dipeptidyl peptidase 6 and 10 subunits reflects selective cell surface Kv4. 2 protein stabilization, " The Journal of Biological Chemistry, vol. 287, no. 12, pp. 9640-9650, 2012.
21. G. Chang, P. Zhang, L. Ye et al., "Protective effects of sitagliptin on myocardial injury and cardiac function in an ischemia/reperfusion rat model, " European Journal of Pharmacology, vol. 718, no. 1-3, pp. 105-113, 2013.
22. L. Chaykovska, K. von Websky, J. Rahnenfuhrer et al., "Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy, " PLoS ONE, vol. 6, no. 11, Article ID e27861, 2011.
23. T. Miyoshi, K. Nakamura, M. Yoshida et al., "Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats, " Cardiovascular Diabetology, vol. 13, Article ID 10. 1186/1475-2840-13-43, p. 43, 2014.
24. T. Matsui, Y. Nishino, M. Takeuchi, and S. Yamagishi, "Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis, " Pharmacological Research, vol. 63, no. 5, pp. 383-388, 2011.
25. R. P. Mason, R. F. Jacob, R. Kubant, A. Ciszewski, J. J. Corbalan, and T. Malinski, "Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats, " Journal of Cardiovascular Pharmacology, vol. 60, no. 5, pp. 467-473, 2012.
26. N. N. Ta, C. A. Schuyler, Y. Li, M. F. Lopes-Virella, and Y. Huang, "DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice, " Journal of Cardiovascular Pharmacology, vol. 58, no. 2, pp. 157-166, 2011.
27. N. Ervinna, T. Mita, E. Yasunari et al., "Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice, " Endocrinology, vol. 154, no. 3, pp. 1260-1270, 2013.
28. G. P. Fadini, E. Boscaro, M. Albiero et al., "The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patientswith type 2 diabetes: Possible role of stromal-derived factor-1α, " Diabetes Care, vol. 33, no. 7, pp. 1607-1609, 2010.
29. V. Darsalia, H. Ortsater, A. Olverling et al., "The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride, " Diabetes, vol. 62, no. 4, pp. 1289-1296, 2013.
30. L. Chaykovska, M. L. Alter, K. von Websky et al., "Effects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-clip hypertension, " Journal of Hypertension, vol. 31, no. 11, pp. 2290-2298, 2013.
31. A. Marney, S. Kunchakarra, L. Byrne, and N. J. Brown, "Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans, " Hypertension, vol. 56, no. 4, pp. 728-733, 2010.
32. P. A. J. Krijnen, N. E. Hahn, I. Kholova et al., "Loss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature ofmyocardial infarction patients, " Basic Research in Cardiology, vol. 107, no. 1, article 233, 2012.
33. P. Hoffmann, P. Bentley, P. Sahota et al., "Vascular origin of vildagliptin-induced skin effects in cynomolgus monkeys: pathomechanistic role of peripheral sympathetic system and neuropeptide Y, " Toxicologic Pathology, vol. 42, no. 4, pp. 684-695, 2014.
34. A. C. C. Girardi, L. E. Fukuda, L. V. Rossoni, G. Malnic, and N. A. Reboucas, "Dipeptidyl peptidase IV inhibition downregulates Na+-H+ exchanger NHE3 in rat renal proximal tubule, " The American Journal of Physiology-Renal Physiology, vol. 294, no. 2, pp. F414-F422, 2008.
35. M. L. Alter, I. M. Ott, K. Von Websky et al., "DPP-4 inhibition on top of angiotensin receptor blockade offers a newtherapeutic approach for diabetic nephropathy, " Kidney and Blood Pressure Research, vol. 36, no. 1, pp. 119-130, 2012.
36. E. K. Jackson, S. J. Kochanek, and D. G. Gillespie, "Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells, " Hypertension, vol. 60, no. 3, pp. 757-764, 2012.
37. M. Kern, N. Kloting, H. G. Niessen et al., "Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity, " PLoS ONE, vol. 7, no. 6, Article ID e38744, 2012.
38. M. Boschmann, S. Engeli, K. Dobberstein et al., "Dipeptidylpeptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients, " Journal of Clinical Endocrinology andMetabolism, vol. 94, no. 3, pp. 846-852, 2009.
39. E. K. Jackson and Z. Mi, "Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension, " Hypertension, vol. 51, no. 6, pp. 1637-1642, 2008.
40. N. N. Ta, Y. Li, C. A. Schuyler, M. F. Lopes-Virella, and Y. Huang, "DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes, " Atherosclerosis, vol. 213, no. 2, pp. 429-435, 2010.
41. D. Reinhold, U. Bank, F. Buhling et al., "Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) specifically suppress proliferation andmodulate cytokine production of strongly CD26 expressing U937 cells, " Immunobiology, vol. 192, no. 1-2, pp. 121-136, 1994.
42. A. Makdissi, H. Ghanim, M. Vora et al., "Sitagliptin exerts an antinflammatory action, " Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 9, pp. 3333-3341, 2012.
43. W. Jungraithmayr, I. DeMeester, V. Matheeussen et al., "Inhibition of CD26/DPP IV attenuates ischemia/reperfusion injury in orthotopicmouse lung transplants: the pivotal role of vasoactive intestinal peptide, " Peptides, vol. 31, no. 4, pp. 585-591, 2010.
44. A. K. Gupta, A. K. Verma, J. Kailashiya, S. K. Singh, and N. Kumar, "Sitagliptin: anti-platelet effect in diabetes and healthy volunteers, " Platelets, vol. 23, no. 8, pp. 565-570, 2012.
45. K. W. Christopherson II, G. Hangoc, C. R. Mantel, and H. E. Broxmeyer, "Modulation of hematopoietic stem cell homing and engraftment by CD26, " Science, vol. 305, no. 5686, pp. 1000-1003, 2004.
46. H. E. Broxmeyer, J. Hoggatt, H. A. Oleary et al., "Dipeptidylpeptidase-IV negatively regulates colony-stimulating factor activity and stress hematopoiesis, " Nature Medicine, vol. 18, no. 12, pp. 1786-1796, 2012.
47. C. Tiruppathi, Y. Miyamoto, V. Ganapathy, R. A. Roesel, G. M. Whitford, and F. H. Leibach, "Hydrolysis and transport of proline-containing peptides in renal brush-border membrane vesicles from dipeptidyl peptidase IV-positive and dipeptidyl peptidase IV-negative rat strains, " Journal of Biological Chemistry, vol. 265, no. 3, pp. 1476-1483, 1990.
48. E. Boonacker and C. J. F. Van Noorden, "Themultifunctional or moonlighting protein CD26/DPPIV, " European Journal of Cell Biology, vol. 82, no. 2, pp. 53-73, 2003.
49. F. M. Keane, T. W. Yao, S. Seelk et al., "Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs, " FEBS Open Bio, vol. 4, pp. 43-54, 2014.
50. D. T. Dang, S. Y. Chun, K. Burkitt et al., "Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition, " Cancer Research, vol. 68, no. 6, pp. 1872-1880, 2008.
51. G. P. Fadini and A. Avogaro, "Cardiovascular effects of DPP-4 inhibition: beyond GLP-1, " Vascular Pharmacology, vol. 55, no. 1-3, pp. 10-16, 2011.
52. B. Bauvois, M. Djavaheri-Mergny, D. Rouillard, J. Dumont, and J. Wietzerbin, "Regulation of CD26/DPPIV gene expression by interferons and retinoic acid in tumor B cells, " Oncogene, vol. 19, no. 2, pp. 265-272, 2000.
53. S. K. Bohm, J. R. Gum Jr., R. H. Erickson, J. W. Hicks, and Y. S. Kim, "Human dipeptidyl peptidase IV gene promoter: tissue-specific regulation from a TATA-less GC-rich sequence characteristic of a housekeeping gene promoter, " Biochemical Journal, vol. 311, no. 3, pp. 835-843, 1995.
54. Y. Suzuki, R. H. Erickson, A. Sedlmayer, S.-K. Chang, Y. Ikehara, and Y. S. Kim, "Dietary regulation of rat intestinal angiotensinconverting enzyme and dipeptidyl peptidase IV, " The American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 264, no. 6, pp. G1153-G1159, 1993.
55. N. Gu, M. Tsuda, T. Matsunaga et al., "Glucose regulation of dipeptidyl peptidase IV gene expression ismediated by hepatocyte nuclear factor-1α in epithelial intestinal cells, " Clinical and Experimental Pharmacology and Physiology, vol. 35, no. 12, pp. 1433-1439, 2008.
56. S. A. Lee, Y. R. Kim, E. J. Yang et al., "CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus, " The Journal of Clinical Endocrinology andMetabolism, vol. 98, no. 6, pp. 2553-2561, 2013.
57. J. Ryskjær, C. F. Deacon, R. D. Carr et al., "Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake, " European Journal of Endocrinology, vol. 155, no. 3, pp. 485-493, 2006.
58. S. K. Malin, H. Huang, A. Mulya, S. R. Kashyap, and J. P. Kirwan, "Lower dipeptidyl peptidase-4 following exercise training plus weight loss is related to increased insulin sensitivity in adults with metabolic syndrome, " Peptides, vol. 47, no. 1, pp. 142-147, 2013.
59. J. M. Lenhard, D. K. Croom, and D. T. Minnick, "Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments, " Biochemical and Biophysical Research Communications, vol. 324, no. 1, pp. 92-97, 2004.
60. A. E. Mast, D. A. Higuchi, Z. Huang, I. Warshawsky, A. L. Schwartz, and G. J. Broze Jr., "Glypican-3 is a binding protein on the HepG2 cell surface for tissue factor pathway inhibitor, " Biochemical Journal, vol. 327, no. 2, pp. 577-583, 1997.
61. J. Davoodi, J. Kelly, N. H. Gendron, and A. E. MacKenzie, "The Simpson-Golabi-Behmel syndrome causative Glypican-3, binds to and inhibits the dipeptidyl peptidase activity of CD26, " Proteomics, vol. 7, no. 13, pp. 2300-2310, 2007.
62. S. Khurana, L. Margamuljana, C. Joseph, S. Schouteden, S. M. Buckley, and C. M. Verfaillie, "Glypican-3-mediated inhibition of CD26 by TFPI: a novel mechanism in hematopoietic stem cell homing and maintenance., " Blood, vol. 121, no. 14, pp. 2587-2595, 2013.
63. D. Lamers, S. Famulla, N. Wronkowitz et al., "Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome, " Diabetes, vol. 60, no. 7, pp. 1917-1925, 2011.
64. Y. Ishibashi, T. Matsui, S. Maeda, Y. Higashimoto, and S.-I. Yamagishi, "Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulinlike growth factor II receptor, " Cardiovascular Diabetology, vol. 12, no. 1, article 125, 9 pages, 2013.
65. J. S. Duke-Cohan, C. Morimoto, J. A. Rocker, and S. F. Schlossman, "A novel form of dipeptidylpeptidase IV found in human serum. Isolation, characterization, and comparison with T lymphocytemembrane dipeptidylpeptidase IV (CD26), " Journal of Biological Chemistry, vol. 270, no. 23, pp. 14107-14114, 1995.
66. N. Busso, N. Wagtmann, C. Herling et al., "Circulating CD26 is negatively associated with inflammation in human and experimental arthritis, " The American Journal of Pathology, vol. 166, no. 2, pp. 433-442, 2005.
67. M. Hildebrandt, M. Rose, J. Ruter, A. Salama, H. Monnikes, and B. F. Klapp, "Dipeptidyl peptidase IV (DP IV, CD26) in patients with inflammatory bowel disease, " Scandinavian Journal of Gastroenterology, vol. 36, no. 10, pp. 1067-1072, 2001.
68. K. Abe, L. Kuo, and Z. Zukowska, "NeuropeptideYis a mediator of chronic vascular and metabolic maladaptations to stress and hypernutrition, " Experimental Biology and Medicine, vol. 235, no. 10, pp. 1179-1184, 2010.
69. X. Pedragosa-Badia, J. Stichel, and A. G. Beck-Sickinger, "Neuropeptide Y receptors: how to get subtype selectivity, " Frontiers in Endocrinology, vol. 4, no. 5, pp. 1-13, 2013.
70. L. E. Kuo, J. B. Kitlinska, J. U. Tilan et al., "Neuropeptide Y acts directly in the periphery on fat tissue and mediates stressinduced obesity and metabolic syndrome, " Nature Medicine, vol. 13, no. 7, pp. 803-811, 2007.
71. C. Huang, C. Shih, N. Tsao et al., "Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells, " British Journal of Pharmacology, vol. 167, no. 7, pp. 1506-1519, 2012.
72. K. Ohnuma, N. Takahashi, T. Yamochi, O. Hosono, N. H. Dang, and C. Morimoto, "Role of CD26/dipeptidyl peptidase IV in human T cell activation and function, " Frontiers in Bioscience, vol. 13, no. 6, pp. 2299-2310, 2008.
73. T. Ohtsuki, H. Tsuda, and C. Morimoto, "Good or evil: CD26 and HIV infection, " Journal of Dermatological Science, vol. 22, no. 3, pp. 152-160, 2000.
74. T. Ishii, K. Ohnuma, A. Murakami et al., "CD26-mediated signaling for T cell activation occurs in lipid rafts through its associationwithCD45RO, " Proceedings of theNationalAcademy of Sciences of the United States of America, vol. 98, no. 21, pp. 12138-12143, 2001.
75. K. Ohnuma, M. Uchiyama, T. Yamochi et al., "Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1, " Journal of Biological Chemistry, vol. 282, no. 13, pp. 10117-10131, 2007.
76. G. R. Flentke, E. Munoz, B. T. Huber, A. G. Plaut, C. A. Kettner, and W. W. Bachovchin, "Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function, " Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 4, pp. 1556-1559, 1991.
77. S. Yan, D. Marguet, J. Dobers, W. Reutter, and H. Fan, "Deficiency of CD26 results in a change of cytokine and immunoglobin secretion after stimulation by pokeweed mitogen, " European Journal of Immunology, vol. 33, no. 6, pp. 1519-1527, 2003.
78. G. R. Lankas, B. Leiting, R. S. Roy et al., "Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9, " Diabetes, vol. 54, no. 10, pp. 2988-2994, 2005.
79. Z. Shah, T. Kampfrath, J. A. Deiuliis et al., "Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis, " Circulation, vol. 124, no. 21, pp. 2338-2349, 2011.
80. J. Zhong, X. Rao, and S. Rajagopalan, "An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease, " Atherosclerosis, vol. 226, no. 2, pp. 305-314, 2013.
81. F. Vittone, A. Liberman, D. Vasic et al., "Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe?/? mice, " Diabetologia, vol. 55, no. 8, pp. 2267-2275, 2012.
82. N. Satoh-Asahara, Y. Sasaki, H. Wada et al., "A dipeptidyl peptidase-IV inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients, "Metabolism:Clinical and Experimental, vol. 62, no. 3, pp. 347-351, 2013.
83. P. C. van Poppel, M. S. Gresnigt, P. Smits, M. G. Netea, and C. J. Tack, "The dipeptidyl peptidase-4 inhibitor vildagliptin does not affect ex vivo cytokine response and lymphocyte function in patients with type 2 diabetesmellitus, " Diabetes Research and Clinical Practice, vol. 103, no. 3, pp. 395-401, 2014.
84. R. Mentlein and E. Heymann, "Dipeptidyl peptidase IV inhibits the polymerization of fibrin monomers, " Archives of Biochemistry and Biophysics, vol. 217, no. 2, pp. 748-750, 1982.
85. F. Briand, Q. Thieblemont, R. Burcelin, and T. Sulpice, "Sitagliptin promotesmacrophage-to-faeces reverse cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETP-apoB100 transgenic mice, " Diabetes, Obesity and Metabolism, vol. 14, no. 7, pp. 662-665, 2012.
86. G. Flock, L. L. Baggio, C. Longuet, and D. J. Drucker, "Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice, " Diabetes, vol. 56, no. 12, pp. 3006-3013, 2007.
87. J. Hsieh, C. Longuet, C. L. Baker et al., "The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice, " Diabetologia, vol. 53, no. 3, pp. 552-561, 2010.
88. M. Monami, C. Lamanna, C. M. Desideri, and E. Mannucci, "DPP-4 inhibitors and lipids: systematic review and meta-analysis, " Advances inTherapy, vol. 29, no. 1, pp. 14-25, 2012.
89. E. Y. Choe, Y. Cho, Y. Choi et al., "The effect of DPP-4 inhibitors on metabolic parameters in patients with type 2 diabetes, " Diabetes andMetabolismJournal, vol. 38, no. 3, pp. 211-219, 2014.
90. T. Rieg, M. Gerasimova, F. Murray et al., "Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice, " The American Journal of Physiology -Renal Physiology, vol. 303, no. 7, pp. F963-F971, 2012.
91. A. Cameron-Vendrig, D. Mundil, and M. Husain, "Antiatherothrombotic effects of dipeptidyl peptidase inhibitors, " Current Atherosclerosis Reports, vol. 16, no. 5, p. 408, 2014.
92. P. C. M. van Poppel, M. G. Netea, P. Smits, and C. J. Tack, "Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes, " Diabetes Care, vol. 34, no. 9, pp. 2072-2077, 2011.
93. C. Hawkes and S. Kar, "The insulin-like growth factor-II/mannose-6-phosphate receptor: Structure, distribution and function in the central nervous system, " Brain Research Reviews, vol. 44, no. 2-3, pp. 117-140, 2004.
94. S. Lim, S. H. Choi, H. Shin et al., "Effect of a dipeptidyl peptidase-iv inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats, " PLoS ONE, vol. 7, no. 4, Article ID e35007, 2012.
95. K. Kanasaki, S. Shi, M. Kanasaki et al., "Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-tomesenchymal transition in a therapeutic regimen, " Diabetes, vol. 63, no. 6, pp. 2120-2031, 2014.
96. M. Monami, B. Ahren, I. Dicembrini, and E. Mannucci, "Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: ametaanalysis of randomized clinical trials, " Diabetes, Obesity and Metabolism, vol. 15, no. 2, pp. 112-120, 2013.
97. S. Wu, I. Hopper, M. Skiba, and H. Krum, "Dipeptidyl peptidase-IV inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55, 141 participants, " Cardiovascular Therapeutics, vol. 32, no. 4, pp. 147-158, 2014.
98. W. B. White, C. P. Cannon, S. R. Heller et al., "Alogliptin after acute coronary syndrome in patients with type 2 diabetes, " The New England Journal ofMedicine, vol. 369, no. 14, pp. 1327-1335, 2013.
99. B. M. Scirica, D. L. Bhatt, E. Braunwald et al., "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus, "The New England Journal ofMedicine, vol. 369, no. 14, pp. 1317-1326, 2013.
100. J. K. Devin, M. Pretorius, H. Nian, C. Yu, F. T. T. Billings, and N. J. Brown, "Substance p increases sympathetic activity during combined Angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition, " Hypertension, vol. 63, no. 5, pp. 951-957, 2014.